Abbott Laboratories Inc. shed a significant drag on its efforts to pick up market-share in the US cardiac rhythm management market with the Feb.1 FDA approval of MRI-conditional labeling for its pacemakers.
Abbott’s CRM business, which it acquired on Jan. 4 as part of its acquisition of St. Jude Medical Inc., fell behind competitors in achieving labeling to support use of...